The K1 capsular polysaccharide from Acinetobacter baumannii Is a potential therapeutic target via passive immunization

Infection and Immunity

Volumn 81, Issue 3, 2013, Pages 915-922

  Russo, Thomas A ^a,c   Beanan, Janet M ^b,c   Olson, Ruth ^b,c   MacDonald, Ulrike ^b,c   Cox, Andrew D ^d   St Michael, Frank ^d   Vinogradov, Evgeny V ^d   Spellberg, Brad ^e   Luke Marshall, Nicole R ^b,c   Campagnari, Anthony A ^b,c  

^a VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^e HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; K1 CAPSULAR POLYSACCHARIDE; MONOCLONAL ANTIBODY; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CAPSULE; BACTERIAL CLEARANCE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; IMMUNOGENICITY; MALE; MASS SPECTROMETRY; MOLECULAR MIMICRY; MOUSE; NEUTROPHIL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OPSONIZATION; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RAT; SEROPREVALENCE; SEROTYPE; SOFT TISSUE INFECTION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTIBODIES, MONOCLONAL; BACTERIAL CAPSULES; BACTERIAL VACCINES; EPITOPES; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, BACTERIAL; IMMUNIZATION, PASSIVE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MICE; RATS; RATS, LONG-EVANS;

EID: 84874700791     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01184-12     Document Type: Article

References (58)

1. Perez F, Endimiani A, Bonomo RA. 2008. Why are we afraid of Acinetobacter baumannii?. Expert Rev. Anti Infect. Ther. 6:269-271.
2. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. 2007. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51:3471-3484.
3. Fournier PE, Richet H. 2006. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin. Infect. Dis. 42:692-699.
4. van Dessel H, Kamp-Hopmans TE, Fluit AC, Brisse S, de Smet AM, Dijkshoorn L, Troelstra A, Verhoef J, Mascini EM. 2002. Outbreak of a susceptible strain of Acinetobacter species 13 (sensu Tjernberg and Ursing) in an adult neurosurgical intensive care unit. J. Hosp. Infect. 51:89-95.
5. Richet H, Fournier PE. 2006. Nosocomial infections caused by Acinetobacter baumannii: a major threat worldwide. Infect. Control Hosp. Epidemiol. 27:645-646.
6. Falagas ME, Karveli EA. 2007. The changing global epidemiology of Acinetobacter baumannii infections: a development with major public health implications. Clin. Microbiol. Infect. 13:117-119.
7. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21:538-582.
8. Anstey NM, Currie BJ, Hassell M, Palmer D, Dwyer B, Seifert H. 2002. Community-acquired bacteremic Acinetobacter pneumonia in tropical Australia is caused by diverse strains of Acinetobacter baumannii, with carriage in the throat in at-risk groups. J. Clin. Microbiol. 40:685-686.
9. Anstey NM, Currie BJ, Withnall KM. 1992. Community-acquired Acinetobacter pneumonia in the Northern Territory of Australia. Clin. Infect. Dis. 14:83-91.
10. Chen MZ, Hsueh PR, Lee LN, Yu CJ, Yang PC, Luh KT. 2001. Severe community-acquired pneumonia due to Acinetobacter baumannii. Chest 120:1072-1077.
11. Garzoni C, Emonet S, Legout L, Benedict R, Hoffmeyer P, Bernard L, Garbino J. 2005. Atypical infections in tsunami survivors. Emerg. Infect. Dis. 11:1591-1593.
12. Maegele M, Gregor S, Steinhausen E, Bouillon B, Heiss MM, Perbix W, Wappler F, Rixen D, Geisen J, Berger-Schreck B, Schwarz R. 2005. The long-distance tertiary air transfer and care of tsunami victims: injury pattern and microbiological and psychological aspects. Crit. Care Med. 33: 1136-1140.
13. Gaynes R, Edwards JR. 2005. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 41:848-854.
14. Roca I, Espinal P, Vila-Farres X, Vila J. 2012. The Acinetobacter baumannii oxymoron: commensal hospital dweller turned pan-drugresistant menace. Front. Microbiol. 3:148.
15. Fishbain J, Peleg AY. 2010. Treatment of Acinetobacter infections. Clin. Infect. Dis. 51:79-84.
16. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18: 268-281.
17. Howard A, O'Donoghue M, Feeney A, Sleator RD. 2012. Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence. 3:243-250.
18. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
19. Boucher, H., Gilbert D, Benjamin D, Bradley J., Murray B, Spellberg B, Talbot G. 2011. 10 x '20 progress: development of new drugs active against resistant Gram-negative bacilli, abstr. LB-27. Abstr. 49th Annu. Meet. Infect. Dis. Soc. Am., Boston, MA.
20. Butler MS, Cooper MA. 2011. Antibiotics in the clinical pipeline in 2011. J. Antibiot. 64:413-425.
21. Hsu JL, Safdar N. 2011. Polyclonal immunoglobulins and hyperimmune globulins in prevention and management of infectious diseases. Infect. Dis. Clin. North Am. 25:773-788.
22. Both L, Banyard AC, van Dolleweerd C, Horton DL, Ma JK, Fooks AR. 2012. Passive immunity in the prevention of rabies. Lancet Infect. Dis. 12:397-407.
23. Luo G, Lin L, Ibrahim AS, Baquir B, Pantapalangkoor P, Bonomo RA, Doi Y, Adams MD, Russo TA, Spellberg B. 2012. Active and passive immunization protects against lethal, extreme drug resistant- Acinetobacter baumannii infection. PLoS One 7:e29446. doi:10.1371/journal.pone.0029446.
24. Fedson DS, Nicolas-Spony L, Klemets P, van der Linden M, Marques A, Salleras L, Samson SI. 2011. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev. Vaccines 10:1143-1167.
25. O'Loughlin RE, Edmond K, Mangtani P, Cohen AL, Shetty S, Hajjeh R, Mulholland K. 2010. Methodology and measurement of the effectiveness of Haemophilus influenzae type b vaccine: systematic review. Vaccine 28:6128-6136.
26. Safadi MA, McIntosh ED. 2011. Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies. Expert Rev. Vaccines 10:1717-1730.
27. Bryant KA, Marshall GS. 2011. Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers. Expert Rev. Vaccines 10:941-950.
28. Engels EA, Lau J. 2000. Vaccines for preventing typhoid fever. Cochrane Database Syst. Rev. CD001261. doi:10.1002/14651858.CD001261.
29. Avci FY, Kasper DL. 2010. How bacterial carbohydrates influence the adaptive immune system. Annu. Rev. Immunol. 28:107-130.
30. Blanchard-Rohner G, Pollard AJ. 2011. Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy. Expert Rev. Vaccines 10:673-684.
31. Russo TA, Luke NR, Beanan JM, Olson R, Sauberan SL, MacDonald U, Schultz LW, Umland TC, Campagnari AA. 2010. The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor. Infect. Immun. 78:3993-4000.
32. Ecker JA, Massire C, Hall TA, Ranken R, Pennella TT, Agasino Ivy C, Blyn LB, Hofstadler SA, Endy TP, Scott PT, Lindler L, Hamilton T, Gaddy C, Snow K, Pe M, Fishbain J, Craft D, Deye G, Riddell S, Milstrey E, Petruccelli B, Brisse S, Harpin V, Schink A, Ecker DJ, Sampath R, Eshoo MW. 2006. Identification of Acinetobacter species and genotyping of Acinetobacter baumannii by multilocus PCR and mass spectrometry. J. Clin. Microbiol. 44:2921-2932.
33. Russo TA, MacDonald U, Beanan JM, Olson R, MacDonald IJ, Sauberan SL, Luke NR, Schultz LW, Umland TC. 2009. Penicillinbinding protein 7/8 contributes to the survival of Acinetobacter baumannii in vitro and in vivo. J. Infect. Dis. 199:513-521.
34. Russo TA, Beanan JM, Olson R, MacDonald U, Luke NR, Gill SR, Campagnari AA. 2008. Rat pneumonia and soft-tissue infection models for the study of Acinetobacter baumannii biology. Infect. Immun. 76: 3577-3586.
35. Westphal O, Jann K. 1965. Bacterial lipopolysaccharide. Methods Carbohydr. Chem. 5:88-91.
36. Vinogradov EV, Van Der Drift K, Thomas-Oates JE, Meshkov S, Brade H, Holst O. 1999. The structures of the carbohydrate backbones of the lipopolysaccharides from Escherichia coli rough mutants F470 (R1 core type) and F576 (R2 core type). Eur. J. Biochem. 261:629-639.
37. St Michael F, Li J, Vinogradov E, Larocque S, Harper M, Cox AD. 2005. Structural analysis of the lipopolysaccharide of Pasteurella multocida strain VP161: identification of both Kdo-P and Kdo-Kdo species in the lipopolysaccharide. Carbohydr. Res. 340:59-68.
38. Campagnari AA, Ducey TF, Rebmann CA. 1996. Outer membrane protein B1, an iron-repressible protein conserved in the outer membrane of Moraxella (Branhamella) catarrhalis, binds human transferrin. Infect. Immun. 64:3920-3924.
39. Loehfelm TW, Luke NR, Campagnari AA. 2008. Identification and characterization of an Acinetobacter baumannii biofilm-associated protein. J. Bacteriol. 190:1036-1044.
40. Haase EM, Campagnari AA, Sarwar J, Shero M, Wirth M, Cumming CU, Murphy TF. 1991. Strain-specific and immunodominant surface epitopes of the P2 porin protein of nontypeable Haemophilus influenzae. Infect. Immun. 59:1278-1284.
41. Russo T, Guenther J, Wenderoth S, Frank M. 1993. Generation of isogenic K54 capsule-deficient Escherichia coli strains through TnphoAmediated gene disruption. Mol. Microbiol. 9:357-364.
42. Russo TA, Beanan JM, Olson R, Genagon SA, Macdonald U, Cope JJ, Davidson BA, Johnston B, Johnson JR. 2007. A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate. Vaccine 25:3859-3870.
43. Russo TA, Beanan JM, Olson R, Macdonald U, Cope JJ. 2009. Capsular polysaccharide and the O-specific antigen impede antibody binding: a potential obstacle for the successful development of an extraintestinal pathogenic Escherichia coli vaccine. Vaccine 27:388-395.
44. Edwards KJ, Allen S, Gibson BW, Campagnari AA. 2005. Characterization of a cluster of three glycosyltransferase enzymes essential for Moraxella catarrhalis lipooligosaccharide assembly. J. Bacteriol. 187: 2939-2947.
45. Russo, TA, Davidson BA, Genagon SA, Warholic NM, Macdonald U, Pawlicki PD, Beanan JM, Olson R, Holm BA, Knight PR, III. 2005. E. coli virulence factor hemolysin induces neutrophil apoptosis and necrosis/lysis in vitro and necrosis/lysis and lung injury in a rat pneumonia model. Am. J. Physiol. Lung Cell. Mol. Physiol. 289:L207-L216.
46. Vinogradov EV, Brade L, Brade H, Holst O. 2003. Structural and serological characterisation of the O-antigenic polysaccharide of the lipopolysaccharide from Acinetobacter baumannii strain 24. Carbohydr. Res. 338:2751-2756.
47. Luke NR, Sauberan SL, Russo TA, Beanan JM, Olson R, Loehfelm TW, Cox AD, St. Michael F, Vinogradov EV, Campagnari AA. 2010. Identification and characterization of a glycosyltransferase involved in Acinetobacter baumannii lipopolysaccharide core biosynthesis. Infect. Immun. 78:2017-2023.
48. Choi AH, Slamti L, Avci FY, Pier GB, Maira-Litran T. 2009. The pgaABCD locus of Acinetobacter baumannii encodes the production of poly-beta-1-6-N-acetylglucosamine, which is critical for biofilm formation. J. Bacteriol. 191:5953-5963.
49. Sharon N. 2007. Celebrating the golden anniversary of the discovery of bacillosamine, the diamino sugar of a bacillus. Glycobiology 17:1150-1155.
50. Wyle FA, Artenstein MS, Brandt BL, Tramont EC, Kasper DL, Altieri PL, Berman SL, Lowenthal JP. 1972. Immunologic response of man to group B meningococcal polysaccharide vaccines. J. Infect. Dis. 126:514-521.
51. Finne J, Leinonen M, Makela PH. 1983. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet ii:355-357.
52. Skurnik D, Davis MR, Jr, Benedetti D, Moravec KL, Cywes-Bentley C, Roux D, Traficante DC, Walsh RL, Maira-Litran T, Cassidy SK, Hermos CR, Martin TR, Thakkallapalli EL, Vargas SO, McAdam AJ, Lieberman TD, Kishony R, Lipuma JJ, Pier GB, Goldberg JB, Priebe GP. 2012. Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection. J. Infect. Dis. 205:1709-1718.
53. Prendergast MM, Moran AP. 2000. Lipopolysaccharides in the development of the Guillain-Barre syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies. J. Endotoxin Res. 6:341-359.
54. Yuki N, Hartung HP. 2012. Guillain-Barre syndrome. N. Engl. J. Med. 366:2294-2304.
55. Moe GR, Tan S, Granoff DM. 1999. Molecular mimetics of polysaccharide epitopes as vaccine candidates for prevention of Neisseria meningitidis serogroup B disease. FEMS Immunol. Med. Microbiol. 26:209-226.
56. Harvey HA, Swords WE, Apicella MA. 2001. The mimicry of human glycolipids and glycosphingolipids by the lipooligosaccharides of pathogenic neisseria and haemophilus. J. Autoimmun. 16:257-262.
57. Jann B, Jann K. 1990. Structure and biosynthesis of the capsular antigens of Escherichia coli. Curr. Top. Microbiol. Immunol. 150:19-42.
58. Orskov F, Orskov I, Jann B, Jann K. 1977. Serology, chemistry, and genetics of O and K antigens of Escherichia coli. Bacteriol. Rev. 41:667-710.